Mendy Ter Avest
Overview
Explore the profile of Mendy Ter Avest including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wolthuis D, Freriksen J, Ter Avest M, Kartha R, de Wildt S, Wijnsma K, et al.
Pediatr Nephrol
. 2025 Feb;
PMID: 39900743
Background: Shiga toxin-producing Escherichia coli hemolytic-uremic syndrome (STEC-HUS) is a severe illness predominantly affecting young children, with limited treatment options beyond supportive care. Eliglustat, approved for Gaucher disease, shows potential...
2.
Ter Avest M, de Boer Z, Langemeijer S, van de Kar N, van de Kar N, de Jonge M, et al.
Blood Adv
. 2025 Jan;
9(6):1280-1285.
PMID: 39820328
No abstract available.
3.
Ter Avest M, Duineveld C, Bouwmeester R, Baas L, van den Heuvel L, Langemeijer S, et al.
Nephrol Dial Transplant
. 2024 Nov;
40(3):598-601.
PMID: 39533120
No abstract available.
4.
Ter Avest M, Langemeijer S, Blijlevens N, van de Kar N, Ter Heine R
Ann Hematol
. 2024 Mar;
103(7):2267-2272.
PMID: 38453703
Pegcetacoplan (Aspaveli®/Empaveli™) is a factor C3 inhibitor that is approved for the treatment of paroxysmal nocturnal hemoglobinuria. An individualized dosing strategy might be useful to improve patient-friendliness and cost-effectiveness of...
5.
Ter Avest M, Steenbreker H, Bouwmeester R, Duineveld C, Wijnsma K, van den Heuvel L, et al.
Clin J Am Soc Nephrol
. 2023 Mar;
18(6):759-766.
PMID: 36913245
Background: Eculizumab is a monoclonal antibody for the treatment of atypical hemolytic uremic syndrome (aHUS). Kidney damage, a common condition in patients with aHUS, may result in proteinuria. Because proteinuria...
6.
Bouwmeester R, Duineveld C, Wijnsma K, Bemelman F, van der Heijden J, van Wijk J, et al.
Kidney Int Rep
. 2023 Jan;
8(1):91-102.
PMID: 36644349
Introduction: The introduction of eculizumab has improved the outcome in patients with atypical hemolytic uremic syndrome (aHUS). The optimal treatment strategy is debated. Here, we report the results of the...
7.
Ter Avest M, Langemeijer S, Blijlevens N, van de Kar N, Ter Heine R
Br J Clin Pharmacol
. 2022 Nov;
89(3):1211-1215.
PMID: 36394176
Ravulizumab is an expensive complement C5-inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria. Recently, a subcutaneous formulation has entered the market, for which the approved dosing regimen results in supratherapeutic...
8.
Ter Avest M, Bouwmeester R, Duineveld C, Wijnsma K, Volokhina E, van den Heuvel L, et al.
Nephrol Dial Transplant
. 2022 Mar;
38(2):362-371.
PMID: 35238929
Background: Eculizumab is a lifesaving yet expensive drug for atypical haemolytic uraemic syndrome (aHUS). Current guidelines advise a fixed-dosing schedule, which can be suboptimal and inflexible in the individual patient....
9.
Karssemeijer E, van der Heijden C, Wolters T, Te Boekhorst B, Ter Avest M, Kramers C
Ned Tijdschr Geneeskd
. 2021 Dec;
165.
PMID: 34854616
Polypharmacy may result in interactions and side effects that lead to morbidity and mortality. Therefore, it is important to evaluate on a regular basis the possibility to stop medication. Sometimes...
10.
Bouwmeester R, Ter Avest M, Wijnsma K, Duineveld C, Ter Heine R, Volokhina E, et al.
Front Immunol
. 2021 Feb;
11:612706.
PMID: 33519821
Background: With the introduction of eculizumab, a C5-inhibitor, morbidity and mortality improved significantly for patients with atypical hemolytic uremic syndrome (aHUS). In view of the high costs, actual needs of...